Clinical Trial

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Name: Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis — clinical trial record (NCT07095465)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 3

View on ClinicalTrials.gov →

Summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Protocol Amendment History 2 changes

notable Trial sites expanded: 15 -> 30 locations 2026-07-25

notable Trial sites expanded: 12 -> 15 locations 2026-05-30

Trial Details

NCT Number	NCT07095465
Lead Sponsor	ACADIA Pharmaceuticals Inc.
Conditions	Lewy Body Dementia Psychosis
Enrollment	126 participants
Start Date	2025-11-14
Primary Completion	2029-02 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-24